| Description |
1 online resource (1058 pages) |
| Series |
Current Topics from the Encyclopedia of Molecular Cell Biology and Molecular Medicine Ser |
|
Current Topics from the Encyclopedia of Molecular Cell Biology and Molecular Medicine Ser
|
| Contents |
Cover; Title Page; Copyright; Contents; Preface; Volume 1; Part I Biopharmaceuticals; Chapter 1 Analogs and Antagonists of Male Sex Hormones; 1 Introduction; 2 Historical; 3 Endogenous Male Sex Hormones; 3.1 Occurrence and Physiological Roles; 3.2 Biosynthesis; 3.3 Absorption and Distribution; 3.4 Metabolism; 3.4.1 Reductive Metabolism; 3.4.2 Oxidative Metabolism; 3.5 Mechanism of Action; 4 Synthetic Androgens; 4.1 Current Drugs on the Market; 4.2 Therapeutic Uses and Bioassays; 4.3 Structure-Activity Relationships for Steroidal Androgens; 4.3.1 Early Modifications |
|
4.3.2 Methylated Derivatives4.3.3 Ester Derivatives; 4.3.4 Halo Derivatives; 4.3.5 Other Androgen Derivatives; 4.3.6 Summary of Structure-Activity Relationships of Steroidal Androgens; 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs); 4.5 Absorption, Distribution, and Metabolism; 4.6 Toxicities; 5 Anabolic Agents; 5.1 Current Drugs on the Market; 5.2 Therapeutic Uses and Bioassays; 5.3 Structure-Activity Relationships for Anabolic Agents; 5.3.1 19-Nor Derivatives; 5.3.2 Dehydro Derivatives; 5.3.3 Alkylated Analogs; 5.3.4 Hydroxy and Mercapto Derivatives |
|
5.3.5 Oxa, Thia, and Aza Derivatives5.3.6 Deoxy and Heterocyclic-Fused Analogs; 5.3.7 Esters and Ethers; 5.3.8 Summary of Structure-Activity Relationships; 5.4 Absorption, Distribution, and Metabolism; 5.5 Toxicities; 5.6 Abuse of Anabolic Agents; 6 Androgen Antagonists; 6.1 Current Drugs on the Market; 6.2 Antiandrogens; 6.2.1 Therapeutic Uses; 6.2.2 Structure-Activity Relationships for Antiandrogens; 6.2.3 Absorption, Distribution, and Metabolism; 6.2.4 Toxicities; 6.3 Enzyme Inhibitors; 6.3.1 5a-Reductase Inhibitors; 6.3.2 17,20-Lyase Inhibitors; 6.3.3 C19 Steroids as Aromatase Inhibitors |
|
7 SummaryAcknowledgments; Chapter 2 Annexins; 1 Diversity and Functions; 2 Structure and Mechanism of Action; 3 Regulation; 4 Applications; References; Chapter 3 Genetic Engineering of Antibody Molecules; 1 Antibody Structure and Engineering; 1.1 The Basic Structure of Antibodies; 1.2 Classes and Subclasses of Antibodies; 2 Technological Milestones in Antibody Engineering; 2.1 Murine Monoclonal Antibodies; 2.2 Chimeric Antibodies; 2.3 Humanized Antibodies; 2.4 Fully Human Antibodies; 3 Expression Systems; 3.1 Prokaryotic Expression Systems; 3.2 Yeast Expression Systems |
|
3.3 Insect Cell Expression Systems3.4 Mammalian Cell Expression Systems; 3.5 Antibody Expression in Transgenic Plants; 3.6 Transgenic Mammals; 4 Variable Region Engineering; 4.1 Improving the Affinity of Recombinant Antibodies; 4.2 Reduction of Immunogenicity; 5 Constant Region Engineering; 5.1 Fc Engineering of IgGs for ADCC and ADCP Functions; 5.2 Fc Engineering of IgGs for CDC Function; 5.3 Antibody Engineering for Altered Half-Life; 5.4 Antibodies of the IgE Class; 6 Structurally Modified Antibodies; 6.1 Antibody Fragments: Fabs and scFvs Monovalent, Bivalent, and Multivalent |
| Notes |
6.2 Bispecific Antibodies |
|
Print version record |
| Subject |
Drug development.
|
|
Molecular pharmacology.
|
|
Translational Research, Biomedical
|
|
Molecular Mechanisms of Pharmacological Action
|
|
Drug Discovery
|
|
Drug development
|
|
Molecular pharmacology
|
| Form |
Electronic book
|
| ISBN |
9783527687190 |
|
352768719X |
|
